CovidChloroV1, Main, Corpus, bibRecord, 000749

Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2.

Identifieur interne : 000749 ( Main/Corpus ); précédent : 000748; suivant : 000750

Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2.

Auteurs : Dipankar Bhattacharyya

Source :

Medical hypotheses [ 1532-2777 ] ; 2020.

RBID : pubmed:33254480

English descriptors

KwdEn :
- Acetates (therapeutic use), Anti-Asthmatic Agents (therapeutic use), Antiviral Agents (therapeutic use), COVID-19 (drug therapy), Cetirizine (therapeutic use), Clinical Trials as Topic (MeSH), Drug Repositioning (MeSH), Histamine H1 Antagonists, Non-Sedating (therapeutic use), Humans (MeSH), Hypersensitivity (drug therapy), Models, Theoretical (MeSH), Patient Safety (MeSH), Quinolines (therapeutic use), Taste (MeSH).
MESH :
- chemical , therapeutic use : Acetates, Anti-Asthmatic Agents, Antiviral Agents, Cetirizine, Histamine H1 Antagonists, Non-Sedating, Quinolines.
- drug therapy : COVID-19, Hypersensitivity.
- Clinical Trials as Topic, Drug Repositioning, Humans, Models, Theoretical, Patient Safety, Taste.

Abstract

It has been hypothesised that antiallergic medications (AAMs) like montelukast and levocetirizine both the two bitter chloro compounds could be repurposed either alone or combinedly as an antiviral against SARS-CoV-2, like chloroquine/hydroxychloroquine (CQ/HCQ), another two bitter chloro compounds. Both AAMs and CQ/HCQ are bitter tasted chloro compounds. Depending on their these two similar physical properties and the safety and efficacy of AAMs by controlling over post viral episodes as comparing with viral inhibitory activities including SARS-CoV-2 by CQ/HCQ, a reposition of AAMs either alone/combinedly could be rationalised as an antiviral approach to nCoV.

DOI: 10.1016/j.mehy.2020.110046
PubMed: 33254480
PubMed Central: PMC7321662

Links to Exploration step

pubmed:33254480

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2.</title>
<author><name sortKey="Bhattacharyya, Dipankar" sort="Bhattacharyya, Dipankar" uniqKey="Bhattacharyya D" first="Dipankar" last="Bhattacharyya">Dipankar Bhattacharyya</name>
<affiliation><nlm:affiliation>Chichuria Institute of Medical Science & Research, Thakurpara, Chichuria, Bethuadahari-II (XVI), Nadia, West Bengal 741 126, India. Electronic address: bhattacharyya952@gmail.com.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:33254480</idno>
<idno type="pmid">33254480</idno>
<idno type="doi">10.1016/j.mehy.2020.110046</idno>
<idno type="pmc">PMC7321662</idno>
<idno type="wicri:Area/Main/Corpus">000749</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000749</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2.</title>
<author><name sortKey="Bhattacharyya, Dipankar" sort="Bhattacharyya, Dipankar" uniqKey="Bhattacharyya D" first="Dipankar" last="Bhattacharyya">Dipankar Bhattacharyya</name>
<affiliation><nlm:affiliation>Chichuria Institute of Medical Science & Research, Thakurpara, Chichuria, Bethuadahari-II (XVI), Nadia, West Bengal 741 126, India. Electronic address: bhattacharyya952@gmail.com.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Medical hypotheses</title>
<idno type="eISSN">1532-2777</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetates (therapeutic use)</term>
<term>Anti-Asthmatic Agents (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>COVID-19 (drug therapy)</term>
<term>Cetirizine (therapeutic use)</term>
<term>Clinical Trials as Topic (MeSH)</term>
<term>Drug Repositioning (MeSH)</term>
<term>Histamine H1 Antagonists, Non-Sedating (therapeutic use)</term>
<term>Humans (MeSH)</term>
<term>Hypersensitivity (drug therapy)</term>
<term>Models, Theoretical (MeSH)</term>
<term>Patient Safety (MeSH)</term>
<term>Quinolines (therapeutic use)</term>
<term>Taste (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetates</term>
<term>Anti-Asthmatic Agents</term>
<term>Antiviral Agents</term>
<term>Cetirizine</term>
<term>Histamine H1 Antagonists, Non-Sedating</term>
<term>Quinolines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
<term>Hypersensitivity</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Drug Repositioning</term>
<term>Humans</term>
<term>Models, Theoretical</term>
<term>Patient Safety</term>
<term>Taste</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">It has been hypothesised that antiallergic medications (AAMs) like montelukast and levocetirizine both the two bitter chloro compounds could be repurposed either alone or combinedly as an antiviral against SARS-CoV-2, like chloroquine/hydroxychloroquine (CQ/HCQ), another two bitter chloro compounds. Both AAMs and CQ/HCQ are bitter tasted chloro compounds. Depending on their these two similar physical properties and the safety and efficacy of AAMs by controlling over post viral episodes as comparing with viral inhibitory activities including SARS-CoV-2 by CQ/HCQ, a reposition of AAMs either alone/combinedly could be rationalised as an antiviral approach to nCoV.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33254480</PMID>
<DateCompleted><Year>2020</Year>
<Month>12</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>03</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2777</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>144</Volume>
<PubDate><Year>2020</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Medical hypotheses</Title>
<ISOAbbreviation>Med Hypotheses</ISOAbbreviation>
</Journal>
<ArticleTitle>Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2.</ArticleTitle>
<Pagination><MedlinePgn>110046</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0306-9877(20)31820-X</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mehy.2020.110046</ELocationID>
<Abstract><AbstractText>It has been hypothesised that antiallergic medications (AAMs) like montelukast and levocetirizine both the two bitter chloro compounds could be repurposed either alone or combinedly as an antiviral against SARS-CoV-2, like chloroquine/hydroxychloroquine (CQ/HCQ), another two bitter chloro compounds. Both AAMs and CQ/HCQ are bitter tasted chloro compounds. Depending on their these two similar physical properties and the safety and efficacy of AAMs by controlling over post viral episodes as comparing with viral inhibitory activities including SARS-CoV-2 by CQ/HCQ, a reposition of AAMs either alone/combinedly could be rationalised as an antiviral approach to nCoV.</AbstractText>
<CopyrightInformation>Copyright © 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhattacharyya</LastName>
<ForeName>Dipankar</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Chichuria Institute of Medical Science & Research, Thakurpara, Chichuria, Bethuadahari-II (XVI), Nadia, West Bengal 741 126, India. Electronic address: bhattacharyya952@gmail.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>06</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Med Hypotheses</MedlineTA>
<NlmUniqueID>7505668</NlmUniqueID>
<ISSNLinking>0306-9877</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000085">Acetates</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018927">Anti-Asthmatic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D039563">Histamine H1 Antagonists, Non-Sedating</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011804">Quinolines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>6U5EA9RT2O</RegistryNumber>
<NameOfSubstance UI="C472067">levocetirizine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>MHM278SD3E</RegistryNumber>
<NameOfSubstance UI="C093875">montelukast</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>YO7261ME24</RegistryNumber>
<NameOfSubstance UI="D017332">Cetirizine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000085" MajorTopicYN="N">Acetates</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018927" MajorTopicYN="N">Anti-Asthmatic Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017332" MajorTopicYN="N">Cetirizine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D039563" MajorTopicYN="N">Histamine H1 Antagonists, Non-Sedating</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006967" MajorTopicYN="N">Hypersensitivity</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008962" MajorTopicYN="N">Models, Theoretical</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061214" MajorTopicYN="N">Patient Safety</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013649" MajorTopicYN="N">Taste</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>06</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>06</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>06</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>12</Month>
<Day>1</Day>
<Hour>1</Hour>
<Minute>2</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>12</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>12</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33254480</ArticleId>
<ArticleId IdType="pii">S0306-9877(20)31820-X</ArticleId>
<ArticleId IdType="doi">10.1016/j.mehy.2020.110046</ArticleId>
<ArticleId IdType="pmc">PMC7321662</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Trop Biomed. 2018 Dec 1;35(4):1115-1122</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33601858</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2009 Mar;81(3):226-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19110001</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Indian Med Assoc. 2010 Jun;108(6):381-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21121394</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pharm (Cairo). 2014;2014:568320</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26556198</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Crit Care Med. 2008 Oct 15;178(8):854-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18583576</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Ther. 2018 Jul;40(7):1096-1107.e1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29945738</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2003 Nov;3(11):722-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14592603</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Microbiol. 2020 Jan 30;10:3079</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32082265</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cochrane Database Syst Rev. 2015 Oct 19;(10):CD008202</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26482324</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Hypotheses. 2020 Sep;142:109828</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32416408</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Forum Infect Dis. 2020 Apr 15;7(4):ofaa130</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32363212</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000749 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000749 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:33254480
   |texte=   Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:33254480" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2.

Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki